Oric Pharmaceuticals, Inc. Common Stock
ORICOric Pharmaceuticals, Inc. is a biotechnology company focused on developing targeted therapies for cancer, with an emphasis on overcoming resistance to existing treatments. Founded with the goal of advancing precision medicine, Oric aims to address unmet needs in oncology by developing novel agents that improve patient outcomes.
Company News
ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, demonstrating strong systemic and CNS activity in NSCLC patients with EGFR exon 20 mutations, with high objective response rates and a competitive safety profile.
The article discusses the promising developments in cancer research, including new therapies and innovative technologies, and highlights recent updates from several biotech companies working on cutting-edge cancer treatments.
The mean of analysts' price targets for Oric Pharmaceuticals (ORIC) points to a 39.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The week after the third Friday of September is historically negative for the S&P 500.
Private investors agreed to spend $85 million to purchase the company's stock.
